CanSino Biologics Enrolls First Patient in Phase 1 Trial for Haemophilus Influenzae Vaccine

MT Newswires Live
2024-11-19

CanSino Biologics (HKG:6185, SHA:688185) enrolled the first patient in its phase 1 clinical trial for its haemophilus influenzae type b freeze-dried conjugate vaccine.

The pathogen has two strains, one of which could cause otitis media or middle ear infection and sinusitis, and another which causes infections secondary to blood infections. It is most present in acute lower respiratory tract infections in children, the filing said.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10